Literature DB >> 2646252

Chinese herb "destagnation" series I: Combination of radiation with destagnation in the treatment of nasopharyngeal carcinoma (NPC): a prospective randomized trial on 188 cases.

G Z Xu1, W M Cai, D X Qin, J H Yan, X L Wu, H X Zhang, Y H Hu, X Z Gu.   

Abstract

The results of a prospective randomized trial on 188 patients with NPC is reported to evaluate the validity of Chinese herbal medicine-Destagnation combined with radiotherapy. Ninety patients were allotted to the Destagnation group (radiation plus Destagnation) and 98, to the control group (radiation only). The 5-year success rate (number surviving minus number recurred but salvaged by re-treatment) of the Destagnation group is 53% (48/90) in comparison to 37% (36/98) of the control group (p less than 0.05). Minor complications of Destagnation included occasional anorexia and frequency of bowel movement. The reduced rate of local recurrence at the primary site in the Destagnation group (14%-13/90) as compared to that of the control group (29%-28/98) (p less than 0.05) suggests that Destagnation may be a radiosensitizer. The similar metastatic rates in both groups; 21% (19/90) in the Destagnation group and 21% (21/98) in the control group may refute the belief that Destagnation enhances hematogenous spread.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2646252     DOI: 10.1016/0360-3016(89)90317-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

1.  A six-herb Chinese medicine composition ointment as a promising candidate for treatment of hypertrophic scars.

Authors:  Zu-Hua Wang; Xue-Yan Sun; Jiao-Jiao Zhang; Francesca Giampieri; Cheng-Ju Jiang; Ting-Ting Feng; Zhi-Wei Wang; Rong-Yi Chen; Maurizio Battino; Ying Zhou
Journal:  Chin Herb Med       Date:  2020-12-29

2.  Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2.

Authors:  S M Sagar; D Yance; R K Wong
Journal:  Curr Oncol       Date:  2006-06       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.